Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

NCT02134301 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Gram-positive Bacterial Infections

Interventions

DRUG: Oritavancin

Sponsor

Melinta Therapeutics, LLC